文献速递乳腺癌放疗放疗物理与技术

乳腺癌放疗联合免疫检查点阻断治疗

Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-05-26

本文综述乳腺癌免疫检查点阻断治疗的临床数据、放疗增强免疫应答的机制、两者联合的临床前与临床证据及在研临床试验。检查点阻断单药在乳腺癌中应答率最高19%,部分应答持久;临床前显示放疗联合检查点抑制可协同增强抗肿瘤疗效并诱导放疗野外应答。结论认为放疗联合检查点阻断可能是乳腺癌有前景的治疗选择。

要点

  • 检查点阻断单药在乳腺癌中应答率最高19%,部分应答持久。
  • 临床前显示放疗联合检查点抑制协同增强抗肿瘤疗效并诱导放疗野外应答。
  • 多项临床试验正在研究检查点抑制联合放疗在乳腺癌中的应用。

核心结论

  • 放疗联合检查点阻断可能是乳腺癌有前景的治疗选择。
  • 可能需要结合化疗和/或放疗等局部策略来增强乳腺癌免疫治疗应答。

研究设计与样本

  • 综述已发表的乳腺癌检查点阻断研究、放疗增强免疫应答机制、检查点阻断联合放疗的临床前与临床数据及当前临床试验格局。

主要发现

  • 检查点阻断治疗临床试验在乳腺癌中显示应答率最高达19%,许多应答持久。
  • 临床前数据表明放疗联合检查点抑制不仅协同增强抗肿瘤疗效,还诱导放疗野外应答。

临床怎么用

  • 基于临床前与临床结果,可考虑将放疗与检查点阻断联合作为乳腺癌的治疗选择,并关注相关临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment with checkpoint inhibitors has shown durable responses in a number of solid tumors, including melanoma, lung, and renal cell carcinoma. However, most breast cancers are resistant to monotherapy with checkpoint inhibitors. Radiation therapy (RT) has been shown to have a number of immunostimulatory effects, including priming the immune system, recruiting immune cells to the tumor environment, and altering the immunosuppressive effects of the tumor microenvironment. RT therefore represents a promising adjuvant therapy to checkpoint blockade in breast cancer. METHODS AND MATERIALS: We review the data from the checkpoint blockade studies on breast cancer reported to date, the mechanisms by which RT potentiates immune responses, the preclinical and clinical data of checkpoint blockade and RT combinations, and the landscape of current clinical trials of RT and immune checkpoint inhibitor combinations in breast cancer. RESULTS: Clinical trials with checkpoint blockade therapy have demonstrated response rates of up to 19% in breast cancer, and many of the responses are durable. Preclinical data indicate that RT combined with checkpoint inhibition synergizes not only to enhance antitumor efficacy but also to induce responses outside of the radiation field. Thus multiple clinical trials are currently investigating the combination of checkpoint inhibition with RT. CONCLUSIONS: The use of combination strategies that incorporate chemotherapy and/or local strategies such as RT may be needed to augment responses to immune therapy in breast cancer. Preclinical and clinical results show that RT in combination with checkpoint blockade may be a promising therapeutic option in breast cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hu ZI, Ho AY, McArthur HL, et al. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816141. doi:10.1016/j.ijrobp.2017.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。